I have spoken to a good friend on the board regarding the

New Post Public Reply Private Reply Replies (3) Message Board
petemantx petemantx #65794
987
I have spoken to a good friend on the board regarding the post to which I am responding as he said many true longs found it quite in bad form. I apologize to all that took it that way and would like to explain myself a bit in regards to it.

In no way did I belittle IPIX nor Brilacidin-IV and I don't see where I voiced any intention of selling my stock cheaply. As to date I have not sold one share of IPIX.
I have lost no faith in the science of our products and expect them both to become among the all time high selling drugs.

In no way did I find fault with Leo.

I do find fault in the process B-CV is going thru but it is what it is so I will no longer make any comments about it as it would serve no purpose. Neither will I speak of other drugs which I feel are being curried favor with vastly lesser results than Brilacidin for the same reason.

I make many posts with the intention of drawing out discussion. As such, I make brash statements that I expect to have thrown back in my face. I expect and accept that, but on this forum that doesn't seem to work so those days are now long gone too.

I did not find any reason anyone would have drawn the conclusion I was going to sell a good portion, or any portion, of my holdings at a low price (which to me is less than multi dollars at the least).

I was told a number of known trashers seemed to like my post but since I have them all on ignore I was unaware of that. Makes me want to puke just thinking about it.

Will wait patiently for Q4 as that seems to now be the time of action and enjoy the rest of the summer with less time spent on IPIX.

Sorry to have upset many.

I do seem a little more hot headed than most on this board so these things happen.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Elevate Your Gaming Experience with Betblast’s New Features

Updated Category News Views 188

Unveiling the New Betblast Features for Gamers In a digital age where online gambling is immensely popular, players are consistently on the lookout for platforms that provide more than just entertainment but also real, significant rewards. One name that has emerged as a favorite among players for offering exceptional wins and rapid payouts is Betblast. As discussions...

Continue Reading
Kinetic Business Introduces Tailored Internet Solutions for SMBs

Updated Category News Views 91

Kinetic Business Introduces an Innovative Internet Solution Kinetic Business is stepping into the spotlight with an exciting new product that caters specifically to the needs of small businesses. Their latest offering, known as Business Ready Internet, aims to revolutionize how small enterprises manage their connectivity, security, and overall operational efficiency....

Continue Reading
The Surge of Ship-to-Shore Cranes: Market Insights Ahead

Updated Category News Views 108

Ship-to-Shore Cranes Market Overview As we look towards the future of the Ship-to-Shore (STS) cranes market, predictions indicate a significant expansion, with market size anticipated to reach USD 4.06 billion by 2032. This growth represents a compound annual growth rate (CAGR) of 4.41% from 2025 to 2032. The increasing emphasis on technological advancements in port...

Continue Reading
Chicago Rivet & Machine Co. Announces Quarterly Dividend Update

Updated Category News Views 93

Chicago Rivet & Machine Co. Announces Dividend Decision Chicago Rivet & Machine Co. (NYSE American: CVR) has made an important announcement regarding its dividend for shareholders. The Board of Directors has declared a quarterly cash dividend of $0.03 per share. This will be paid out to all shareholders who are recorded as of December 5 of the current fiscal year. While...

Continue Reading
Insights on the AstraZeneca PLC Class Action and Investor Rights

Updated Category News Views 140

Understanding the AstraZeneca PLC Class Action A class action lawsuit has been initiated on behalf of stockholders who purchased shares of AstraZeneca PLC (NASDAQ: AZN) between specific dates. Robbins LLP is actively reminding these investors of the critical lead plaintiff deadline. This class action highlights important allegations surrounding AstraZeneca and offers...

Continue Reading